Latest Headlines

  1. NorthStrive Biosciences Announces Positive Results From Phase III Of AI-Driven Drug Discovery Program With Yuva Biosciences 7/1/2026

    NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) ("PMGC" or the "Company"), today announced positive results from Phase III of its AI-driven drug discovery program with strategic partner Yuva Biosciences, Inc. ("Yuva Biosciences").

  2. Insilico Medicine Announces Collaboration With Takeda To Advance Strategic AI Drug Discovery 7/1/2026

    Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to use its proprietary end-to-end platform, Pharma.AI, to advance drug candidates across the company's therapeutic areas.

  3. Lonza Expands HPAPI Capacity In Visp, Further Supporting Its Position In Payload-Linker Manufacturing 6/30/2026
  4. Altasciences Supports Key Development Milestone For Steel Therapeutics' Lead Therapeutic Candidate, Fizurex 6/30/2026

    Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex, for the treatment of anal fissures.

  5. Tsingke Biotech Hosts Shanghai Salon On Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics 6/30/2026

    Tsingke Biotech recently hosted the Oligonucleotide Drug Salon at the Hilton Shanghai Zhangjiang, bringing together experts from academia, biopharmaceutical companies, investment firms, and industry service organizations to discuss technological innovation, CMC development, delivery technologies, regulatory strategies, and commercialization pathways in the rapidly evolving field of oligonucleotide therapeutics.

  6. Inductive Bio Joins Anthropic's Connector Ecosystem For Life Sciences, Surfacing State-Of-The-Art ADMET Prediction To Drug Discovery Scientists Through Claude 6/30/2026

    Inductive Bio, an AI drug discovery partner developing virtual chemistry labs, today announced that it has joined Anthropic's life sciences ecosystem and launched a Model Context Protocol (MCP) connector that makes its ADMET (Absorption, Distribution, Metabolism, Excretion, & Toxicity) prediction models accessible directly within Claude.

  7. Enhertu Approved In The EU As First Tumor Agnostic HER2 Directed Therapy And Antibody Drug Conjugate For Patients With Previously Treated HER2 Positive Metastatic Solid Tumors 6/29/2026

    Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options.

  8. Key Milestone Achieved: NDA For Sumecigrel Capsule, An Antiplatelet Innovative Drug By Vcare Pharmatech, Officially Accepted 6/26/2026

    Recently, the NDA for Sumecigrel Capsule (formerly known as Vicagrel), a Class 1 innovative antiplatelet drug developed by Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech), has been officially accepted by the NMPA.

  9. Biolevate To Advance AI-Native Drug Discovery Workflows With NVIDIA BioNeMo Agent Toolkit 6/25/2026

    Biolevate, an AI-native knowledge platform company for life sciences, today announced it is building with the NVIDIA BioNeMo Agent Toolkit to support the next phase of its agentic discovery roadmap.

  10. VeriSIM Life Formalizes Research Collaboration With FDA/NCTR, Advancing The Next Generation Of Mechanistic AI For Drug Development 6/25/2026

    Drug development remains one of the most resource-intensive and failure-prone endeavors in modern science.